HIV

The Pharmacy Times® HIV Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of HIV, a virus that attacks the body's immune system and, if left untreated, can lead to AIDS.

PQA Launches New HIV Medication Use, Quality Measure Course

May 18, 2022

Video

There are other courses available on HIV, but PQA's surveys the 13 medication related quality measures out there for HIV.

FDA Lifts Clinical Hold on Lenacapavir for HIV Treatment and PrEP

May 17, 2022

Article

The FDA previously placed a clinical hold on lenacapavir in borosilicate vials in all clinical studies because of emerging concerns about the compatibility of vials made of borosilicate glass.

HIV Remission Achieved in Patient Who Underwent Specialized Stem Cell Transplant

May 11, 2022

Article

After 14 months without ART, a patient with HIV only had transient detection of trace levels of HIV DNA in her blood cells after a stem cell transplant for acute myeloid leukemia.

Computer Cognitive Training May Improve Brain Functions for Individuals With HIV

May 03, 2022

Article

Results of a meta-analysis of randomized clinical trials published in JAMA shows improvement in 6 of 8 domains.

Clinical Overview: Cabenuva for HIV

April 28, 2022

Article

Cabotegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral DNA integration.

Trial to Evaluate Anti-Cytomegalovirus Drug in Treating Inflammation in Patients With HIV

April 25, 2022

Article

Letermovir has been approved by the FDA to prevent severe CMV in patients who are asymptomatic and undergoing allogeneic hematopoietic stem cell transplants.

HIV Testing Frequency Among PrEP Users Lower Than Recommended

April 18, 2022

Article

PrEP use has been associated with lowering HIV infections worldwide, however use of the treatment alone is not sufficient to prevent HIV from spreading.

Clinical Overview: Cabotegravir (Apretude) for HIV Pre-Exposure Prophylaxis

April 15, 2022

Article

Cabotegravir is the only current HIV-1 PrEP medication that does need to be taken daily.

Impact of Long-Acting HIV Prevention Drugs

April 01, 2022

Video

A panel of experts discuss the role of PrEP in HIV prevention with a focus on current and newly approved options.

FDA Approves Triumeq PD for Children With HIV

March 31, 2022

Article

Triumeq is a tablet containing 50 mg of dolutegravir, 600 mg of abacavir, and 300 mg of lamivudine.